1-27383221-G-A
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_001330448.1(CD164L2):c.19C>T(p.Arg7Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000285 in 1,545,922 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.000026 ( 0 hom., cov: 31)
Exomes 𝑓: 0.000029 ( 0 hom. )
Consequence
CD164L2
NM_001330448.1 missense
NM_001330448.1 missense
Scores
2
8
9
Clinical Significance
Conservation
PhyloP100: 1.61
Genes affected
CD164L2 (HGNC:32043): (CD164 molecule like 2) Predicted to be integral component of membrane. Predicted to be active in cytoplasmic vesicle. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 0 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.25826082).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CD164L2 | NM_001330448.1 | c.19C>T | p.Arg7Cys | missense_variant | 1/6 | ENST00000374030.3 | NP_001317377.1 | |
CD164L2 | NM_207397.5 | c.19C>T | p.Arg7Cys | missense_variant | 1/5 | NP_997280.2 | ||
CD164L2 | XM_011541441.2 | c.19C>T | p.Arg7Cys | missense_variant | 1/6 | XP_011539743.1 | ||
CD164L2 | XR_241190.4 | n.113C>T | non_coding_transcript_exon_variant | 1/7 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CD164L2 | ENST00000374030.3 | c.19C>T | p.Arg7Cys | missense_variant | 1/6 | 5 | NM_001330448.1 | ENSP00000363142.1 | ||
CD164L2 | ENST00000374027.7 | c.19C>T | p.Arg7Cys | missense_variant | 1/5 | 1 | ENSP00000363139.3 | |||
CD164L2 | ENST00000374025.4 | n.86C>T | non_coding_transcript_exon_variant | 1/3 | 2 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152278Hom.: 0 Cov.: 31
GnomAD3 genomes
AF:
AC:
4
AN:
152278
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000274 AC: 39AN: 142316Hom.: 0 AF XY: 0.000261 AC XY: 20AN XY: 76544
GnomAD3 exomes
AF:
AC:
39
AN:
142316
Hom.:
AF XY:
AC XY:
20
AN XY:
76544
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000287 AC: 40AN: 1393532Hom.: 0 Cov.: 31 AF XY: 0.0000305 AC XY: 21AN XY: 687460
GnomAD4 exome
AF:
AC:
40
AN:
1393532
Hom.:
Cov.:
31
AF XY:
AC XY:
21
AN XY:
687460
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000262 AC: 4AN: 152390Hom.: 0 Cov.: 31 AF XY: 0.0000134 AC XY: 1AN XY: 74522
GnomAD4 genome
AF:
AC:
4
AN:
152390
Hom.:
Cov.:
31
AF XY:
AC XY:
1
AN XY:
74522
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 03, 2023 | The c.19C>T (p.R7C) alteration is located in exon 1 (coding exon 1) of the CD164L2 gene. This alteration results from a C to T substitution at nucleotide position 19, causing the arginine (R) at amino acid position 7 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Pathogenic
DEOGEN2
Benign
.;T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Benign
D;D
M_CAP
Pathogenic
D
MetaRNN
Benign
T;T
MetaSVM
Benign
T
MutationAssessor
Uncertain
M;M
PrimateAI
Uncertain
T
PROVEAN
Benign
N;N
REVEL
Benign
Sift
Uncertain
D;D
Sift4G
Uncertain
D;D
Polyphen
0.99
.;D
Vest4
MutPred
Gain of catalytic residue at P6 (P = 0.0648);Gain of catalytic residue at P6 (P = 0.0648);
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at